Octave Specialty Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OSG research report →
Range $10 – $18
Price Chart
About the company
Octave Specialty Group, Inc. functions as a financial services holding company, organizing its operations into two distinct divisions. Its Specialty Property and Casualty Insurance segment delivers specialized program insurance, primarily focusing on coverage for commercial and personal liability exposures.
- CEO
- Claude LeBlanc
- IPO
- 2013
- Employees
- 483
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on OSG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $208.63M
- P/E
- -2.91
- Fwd P/E
- 22.54
- PEG
- -0.01
- P/S
- 0.62
- P/B
- 0.31
- EV/EBITDA
- -1793.46
- Div Yield
- 0.00%
- Gross Margin
- 88.36%
- Op Margin
- -17.46%
- Net Margin
- -12.44%
- ROE
- -6.01%
- ROIC
- -22.39%
Latest fiscal year · YoY change
- Revenue
- $251.22M+6.5%
- Gross Profit
- $204.03M+106.8%
- Op Income
- $-101,014,000
- Net Income
- $-240,916,000+56.7%
- EPS
- $-5.93+50.0%
- OCF Growth
- -6961.3%
- FCF Growth
- -6961.3%
- 52W High
- $9.19
- 52W Low
- $3.88
- 50D MA
- $4.75
- 200D MA
- $5.15
- Beta
- 0.86
- RSI (14)
- 42
- Avg Volume
- 496.55K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Octave posted broad year-over-year improvement in Q3, led by strong insurance distribution growth and better Everspan profitability, while reaffirming confidence in meeting or exceeding key 2026 targets.· November 10, 2026
- Insurance distribution revenue rose 35% to $58 million, driven by 23% organic growth and the ArmadaCare acquisition.
- Consolidated results improved sharply year over year: net loss to shareholders narrowed to $13.8 million, or $0.31 per share, from $31.7 million, or $0.65 per share.
- Adjusted EBITDA to shareholders turned positive at $3.3 million versus negative $2.9 million a year ago; adjusted net loss narrowed to $1.3 million from $10 million.
- Everspan adjusted EBITDA to shareholders was $2.2 million versus less than $0.1 million last year, with net premiums written up 44% and earned premiums up 52%.
- Management said it now expects to exceed the $45 million full-year adjusted EBITDA guide for insurance distribution and believes Everspan can meet or beat its $6 million adjusted EBITDA target.
Octave reported Q3 net loss to shareholders of $13.8 million, or $0.31 per share, versus a $31.7 million loss, or $0.65 per share, in Q3 2025. Consolidated EBITDA to shareholders was negative $1.8 million versus negative $20.1 million a year ago, and adjusted EBITDA to shareholders was $3.3 million versus negative $2.9 million. Consolidated adjusted net loss to shareholders narrowed to $1.3 million, or $0.03 per share, from $10 million, or $0.21 per share. Insurance distribution revenue was $58 million, up 35%, with organic growth of 23%; adjusted EBITDA to shareholders rose nearly 40% to $8.3 million, with margin at 14.2%. Everspan gross premiums written were $99 million, up 2%, while net premiums written and earned were each $26 million, up 44% and 52%, respectively; its combined ratio was 100.6% versus 112.9% a year ago. Management said insurance distribution should exceed its $45 million adjusted EBITDA guidance for 2026, Everspan may come in slightly under its $410 million gross premiums written guidance, Everspan is well positioned to meet or beat its $6 million adjusted EBITDA guidance, and corporate adjusted expenses remain on track for about $29.5 million. The company also said it remains on track for 2026 to be the first year it expects positive adjusted net income per share and reiterated confidence in reaching $80 million consolidated adjusted EBITDA to shareholders in 2028.
Claude LeBlanc framed the quarter as evidence that Octave’s diversified MGA platform is gaining momentum despite a softer P&C market. He emphasized strong organic growth, product adjacency launches, capacity relationships, and the role of A&H as a buffer against property and casualty pressure. His tone was confident and forward-looking, highlighting 2027 capacity already largely lined up, AI-enabled underwriting improvements, and continued discipline around specialty niches and underwriting quality.
David Trick focused on the sharp improvement in financial performance and reiterated multiple guideposts. He cited insurance distribution organic growth of 35% year to date, said the business is on track to exceed the full-year 25%+ organic growth guide, and stated adjusted EBITDA for the segment should exceed $45 million. He also noted Everspan gross premiums written may finish slightly below the $410 million target, but adjusted EBITDA should meet or beat $6 million, while corporate adjusted expenses were $7.3 million in the quarter and $22.5 million year to date, keeping the company on track for roughly $29.5 million full-year adjusted corporate expense. He added that net leverage fell below 3x at September 30, giving more flexibility for strategic actions such as minority interest buy-ins and noncore asset sales.
Analysts asked about the seasonal timing of distribution fees, ArmadaCare’s impact on organic growth, the pace of Everspan growth versus the $410 million premiums guide, and whether team recruitment remains attractive in a softer market. Management said distribution fees should be more consistent in Q4, closer to Q3 levels, and that ArmadaCare is seasonal but should become a more meaningful organic-growth driver in 2027. On Everspan, they said Q4 growth should be in line to better than Q3 depending on new-program ramp, while confirming that team interest in joining Octave remains healthy, especially in the U.S. and increasingly in Europe.
The bull case from this call is that Octave is showing broad-based execution in a softer pricing environment: distribution growth is still running well above market, margins are improving, and management believes the business can keep compounding through 2027 with its capacity largely in place. The company also pointed to AI-driven underwriting, new product adjacencies, and A&H momentum as additional growth engines.
The main risks discussed were continued P&C market softening, especially in property and energy, which could pressure growth and pricing. Everspan is still carrying some adverse development from legacy commercial auto, and gross premiums written may come in slightly below the full-year target. Management also noted de novo MGA investments are still a drag today, and future growth depends on new-program ramp and disciplined team selection rather than large acquisitions.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.2%
- Shares Outstanding
- 45.06M
- Float Shares
- 42.46M
of shares held by institutions
131 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 3.83M | ▼ 395.60K |
Held by 106 ETFs
Biggest fund positions in OSG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 3, 26 | LeBlanc Claude | other | 11,628 |
| Oct 3, 26 | LeBlanc Claude | other | 15,229 |
| Oct 3, 26 | LeBlanc Claude | other | 8,421 |
| Oct 3, 26 | LeBlanc Claude | other | 11,638 |
| Oct 3, 26 | LeBlanc Claude | other | 15,229 |
| Oct 3, 26 | LeBlanc Claude | other | 221,188 |
| Oct 3, 26 | LeBlanc Claude | other | 232,816 |
| Oct 3, 26 | Smith R Sharon | other | 2,539 |
| Oct 3, 26 | Smith R Sharon | other | 2,539 |
| Oct 3, 26 | Smith R Sharon | other | 52,894 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OSG coverage
Recent articles, reports, and earnings notes.
No research on OSG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OSG report →Capacity Marine Appoints Damon Vaughan President
businesswire.com · Nov 19
Does Octave Specialty (OSG) Have the Potential to Rally 120.6% as Wall Street Analysts Expect?
zacks.com · Nov 12
What Octave Specialty Group (OSG) Said on Its Q3 Earnings Call
marketbeat.com · Nov 10
Octave Specialty Group, Inc. (OSG) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Octave Specialty Group (OSG) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 9
Octave Specialty Group Reports Third Quarter 2026 Results
businesswire.com · Nov 9
Analyzing Octave Specialty Group (NYSE:OSG) & Investors Title (NASDAQ:ITIC)
defenseworld.net · Nov 3
Head-To-Head Review: Octave Specialty Group (NYSE:OSG) vs. Scor (OTCMKTS:SCRYY)
defenseworld.net · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.